PHIO Phio Pharmaceuticals Corp. Net earnings per share growth forecast for next year
A team of leading geneticists at Phio Pharmaceuticals is creating high-tech developments in the field of oncology. This research formed the basis for clinical trials of self-delivering molecules designed to combat tumors. Growth prospects for EPS for the next fiscal year, where the current figure is 47.20, reflect market expectations. This will result in the development of an immunotherapy ecosystem based on the INTASYL platform with exclusive treatment protocols.
Analytical breakdowns for Phio Pharmaceuticals
- share price and consensus valuation forecast:
- market capitalization data:
- company book value details:
- company total debt and liquidity indicators:
Total Debt to Capital Phio Pharmaceuticals|PHIO - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Phio Pharmaceuticals Corp|PHIO - Company Cumulative Debt|Debt to Book Value Phio Pharmaceuticals Corp.|PHIO - Company Long-Term Debts|Company Current Liabilities Phio Pharmaceuticals|Quick Ratio phiopharma.com
- net income and valuation ratios data:
PHIO - Net Financial Result|Projected Future Earnings Phio Pharmaceuticals|PHIO - Price to Earnings Ratio|Forward P/E Multiple RXi Pharmaceuticals|PHIO - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Phio Pharmaceuticals Corp|PHIO - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months Phio Pharmaceuticals|PHIO - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months phiopharma.com|PHIO - Earnings per share trend in current year|Earnings growth forecast for next year Phio Pharmaceuticals
- sales volume and revenue indicators:
Fundamental company analysis:phiopharma.com
This indicator measures analysts' average expectations for earnings per share growth rates, allowing for the identification of revisions to the asset's fundamental value. For Phio Pharmaceuticals (PHIO), the trend in consensus EPS forecasts for the coming year reflects market confidence in the success of RNA therapy amid patent pressure from biotech behemoths. Sharp fluctuations in this metric signal a critical shift in the investment profile and the degree of risk regarding capital freeze.
Main competitors
TEM (Tempus) - Earnings growth forecast for next year|Projected earnings per share growth rate for next year QGEN (Qiagen)|Earnings growth forecast for next year IONS|RGEN (Repligen) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year aviditybiosciences.com RNA|CRISPR (CRSP) - Expected net earnings per share growth next year|genedx.com - Earnings growth forecast for next year|Expected earnings per share trend next year RARE (ultragenyx.com)|BEAM: Earnings growth forecast for next year|Sarepta - Expected earnings per share trend next year|TWST (twistbioscience.com) - Earnings growth forecast for next year|Projected earnings per share growth rate for next year TXG (10x Genomics Corp)|Earnings growth forecast for next year NTLA|Earnings growth forecast for next year Stoke Therapeutics, Inc. (STOK)|Net earnings per share growth forecast for next year BioLife BLFS|WVE - Expected earnings per share growth for next year|Maze Therapeutics Corp - Earnings growth forecast for next year|Sionna Pharma - Projected earnings per share increase next year|Prime Medicine (PRME) - Net earnings per share growth forecast for next year|tayshagtx.com (TSHA) - Earnings growth forecast for next year|Net earnings per share growth forecast for next year uniQure Corp|MGTX: Expected earnings per share trend next year|Earnings growth forecast for next year RGNX|Consensus forecast of earnings per share growth for next year Solid Corp|Earnings growth forecast for next year OCGN (ocugen.com)|PACB (Pacific Biosciences) - Net earnings per share change forecast for next year|Benitec Biopharma Inc - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year Design Therapeutics, Inc. DSGN|Rocket Corp (RCKT) - Net earnings per share growth forecast for next year|4D Molecular Therapeutics (FDMT) - Earnings growth forecast for next year|LXEO (Lexeo Therapeutics, Inc.) - Earnings growth forecast for next year|Expected net earnings per share growth next year korrobio.com KRRO|Expected earnings per share growth for next year EDIT (Editas Medicine, Inc.)|Silence Therapeutics plc - Projected earnings per share growth rate for next year|Net earnings per share growth forecast for next year ProQR Therapeutics N.V. PRQR|Consensus forecast of earnings per share growth for next year Codexis, Inc. (CDXS)|SGMO - Net earnings per share growth forecast for next year|nautilus.bio - Projected earnings per share increase next year|Metagenomi, Inc (MGX) - Net earnings per share growth forecast for next year|Projected earnings per share growth rate for next year DTIL|Net earnings per share growth forecast for next year Generation Bio|Earnings growth forecast for next year Boundless Bio Inc|Net earnings per share growth forecast for next year Exicure Corp (XCUR)|Consensus forecast of earnings per share growth for next year Imunon|Earnings growth forecast for next year MBIO (Mustang Bio Corp)|Projected earnings per share increase next year RNAZ (TransCode Therapeutics)|BNGO - Net earnings per share growth forecast for next year|APDN: Net earnings per share growth forecast for next year|BLUE: Earnings growth forecast for next year|Expected earnings per share growth for next year ImmunoPrecise Antibodies|OMGA (Omega Therapeutics, Inc.) - Earnings growth forecast for next year|Singular Genomics (OMIC) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Regulus (RGLS)|SYRS (Syros Pharmaceuticals, Inc) - Expected earnings per share trend next year|Telesis Bio, Inc. - Expected earnings per share growth for next year|TCON: Projected earnings per share growth rate for next year|Unity Biotechnology Inc. - Earnings growth forecast for next year
